How should PHESGO (pertuzumab, trastuzumab, hyaluronidase) be administered in patients with extreme body weight?

PHESGO Administration in Extreme Body Weight Patients

PHESGO is administered as a fixed dose regardless of body weight—no dose adjustments are required for patients at extremes of body weight. 1

Fixed-Dose Regimen (Weight-Independent)

The FDA-approved dosing for PHESGO is standardized across all patients:

• Initial dose: 1,200 mg pertuzumab/600 mg trastuzumab/30,000 units hyaluronidase (15 mL) subcutaneously over ~8 minutes
• Maintenance dose: 600 mg pertuzumab/600 mg trastuzumab/20,000 units hyaluronidase (10 mL) subcutaneously over ~5 minutes every 3 weeks 1

This represents a fundamental departure from weight-based IV dosing and is explicitly stated in the prescribing information: "No dose adjustments for PHESGO are required for patient body weight or for concomitant chemotherapy regimen." 1

Pharmacokinetic Evidence Supporting Fixed Dosing

The FeDeriCa trial demonstrated that subcutaneous PHESGO achieves non-inferior drug exposure compared to weight-based IV administration. The geometric mean ratio for pertuzumab trough concentration was 1.22 (90% CI: 1.14-1.31), and for trastuzumab was 1.33 (90% CI: 1.24-1.43)—both exceeding the non-inferiority threshold. 2

Body Weight Impact on Exposure

While pharmacokinetic modeling shows some exposure variability across weight extremes, these differences are not considered clinically relevant:

• Low body weight (<58 kg): Trastuzumab AUC approximately 33% higher with SC versus IV
• High body weight (>77 kg): Trastuzumab AUC approximately 24% lower with SC versus IV 1

Despite these numerical differences, the FDA and regulatory agencies concluded no dose adjustments are warranted because:

1. Efficacy outcomes (pathological complete response rates) were comparable across weight ranges 2
2. Safety profiles remained similar regardless of body weight 1
3. The absolute bioavailability was 71% for pertuzumab and 77% for trastuzumab, with consistent steady-state achievement 1

Safety Considerations in Extreme Body Weight

There is no evidence of increased cardiotoxicity in low-body-weight patients receiving fixed-dose PHESGO. 3 The concern about toxicity in lighter patients has not materialized in clinical practice, though this may be confounded by higher cardiovascular comorbidities in heavier patients 3.

For obese patients, the ASCO guideline on systemic therapy dosing explicitly recommends full weight-based dosing for IV chemotherapy should be offered regardless of obesity status 4. However, PHESGO's fixed-dose formulation bypasses this consideration entirely—the subcutaneous route with hyaluronidase-facilitated absorption provides adequate exposure even in higher-weight patients 5.

Practical Administration Algorithm

For ALL patients regardless of weight:

1. First dose: Administer 1,200 mg/600 mg/30,000 units (15 mL) SC in the thigh over ~8 minutes
2. Observe: 30 minutes post-initial dose for hypersensitivity/administration reactions
3. Subsequent doses: Administer 600 mg/600 mg/20,000 units (10 mL) SC every 3 weeks over ~5 minutes
4. Observe: 15 minutes after each maintenance dose

No calculations, no adjustments, no weight-based modifications. 1

Common Pitfalls to Avoid

• Do not attempt to adjust doses based on BSA or weight—this contradicts FDA labeling and the evidence base supporting fixed dosing 1
• Do not substitute PHESGO for IV pertuzumab/trastuzumab using weight-based calculations—these are distinct formulations with different PK profiles 1
• Do not withhold PHESGO from very obese patients due to underdosing concerns—the fixed dose achieves therapeutic concentrations even at higher body weights 1, 2
• Do not reduce doses in very low-weight patients due to toxicity fears—clinical trials showed no increased adverse events in this population 3, 2

Transitioning from IV to SC Formulation

Patients currently on IV pertuzumab/trastuzumab can transition to PHESGO:

• If <6 weeks since last IV dose: Give maintenance dose (600 mg/600 mg)
• If ≥6 weeks since last IV dose: Give initial dose (1,200 mg/600 mg), then maintenance 1

This transition strategy applies uniformly regardless of patient weight 1.

Clinical Context

The shift to fixed-dose SC administration reflects a broader evolution in antibody delivery, where hyaluronidase-facilitated formulations enable consistent exposure without weight-based calculations 5. This approach has been validated across multiple therapeutic antibodies in oncology, with PHESGO representing one of the most extensively studied examples 6.

The evidence consistently supports that extreme body weight—whether very low or very high—does not require dose modification of PHESGO. The fixed-dose regimen provides adequate exposure, comparable efficacy, and acceptable safety across the full spectrum of body weights encountered in clinical practice.